Reactive Arthritis

Reactive arthritis is an inflammatory joint disease triggered by an infection elsewhere in the body — most often in the gut or genitourinary tract. The infection comes first; the arthritis follows weeks later, driven by a misdirected immune response. Once called Reiter's syndrome, the name was abandoned due to its eponym's Nazi war crimes. Understanding the triggers, the genetic susceptibility factor HLA-B27, and the treatment options gives patients the best chance of a full recovery.

Overview and Definition — Formerly Reiter's Syndrome
Epidemiology
Triggering Infections — Chlamydia, Salmonella, Shigella, Campylobacter, Yersinia
Pathophysiology and HLA-B27 Association
Symptoms — The Classic Triad and Beyond
Diagnosis — Clinical Criteria and Tests
Treatment — NSAIDs, Antibiotics, DMARDs
Natural and Nutritional Approaches
Disease Course and Prognosis
Complications
Prevention — Infection Control
Key Research Papers
Connections
Featured Videos

Overview and Definition — Formerly Reiter's Syndrome

Reactive arthritis is a sterile inflammatory arthritis that develops as a consequence of an infection in a distant site — typically the genitourinary tract or the gastrointestinal tract. "Sterile" means that no live organisms are found in the joint itself; the joint inflammation is driven by an immune response to bacterial antigens that have traveled from the original infection site. This distinguishes reactive arthritis from septic arthritis, where bacteria are directly present in the joint.

The condition was historically called Reiter's syndrome, named after Hans Reiter, a German physician who described the triad of arthritis, urethritis, and conjunctivitis in a soldier in 1916. However, historical investigation revealed that Hans Reiter was a member of the Nazi party who authorized and oversaw medical experiments on concentration camp prisoners during World War II, resulting in deaths. In recognition of these crimes, the medical community formally abandoned the eponym in the 1990s and 2000s, replacing it with the descriptive term reactive arthritis. Today, use of "Reiter's syndrome" is considered inappropriate in clinical and academic settings.

Reactive arthritis belongs to a family of conditions known as seronegative spondyloarthropathies — inflammatory joint diseases that are negative for rheumatoid factor and are strongly associated with the genetic marker HLA-B27. Other members of this group include ankylosing spondylitis, psoriatic arthritis, and enteropathic arthritis. Reactive arthritis shares with these conditions a tendency to affect the axial skeleton and entheses (the points where tendons and ligaments attach to bone) in addition to peripheral joints.

Epidemiology

Reactive arthritis is uncommon but not rare. Estimates of incidence vary widely depending on the triggering infection and the population studied. In Western countries, where Chlamydia trachomatis is the most common sexually transmitted infection, reactive arthritis complicates approximately 1–3% of chlamydial urethritis cases. After foodborne outbreaks caused by Salmonella, Shigella, or Campylobacter, the rate of post-infectious arthritis is higher — roughly 2–7% of those infected develop the condition.

The disease most commonly affects young adults aged 20–40 years. In genitourinary-triggered cases, men are affected more often than women, partly because men are more likely to be symptomatic with urethritis (making diagnosis easier) and partly reflecting patterns of sexual behavior and infection. In gastrointestinal-triggered cases, the sex ratio is roughly equal. Reactive arthritis is more prevalent in populations with a high carrier rate of HLA-B27, such as Scandinavian populations, than in populations where HLA-B27 is less common, such as sub-Saharan Africans.

Because many cases are mild and self-limited, reactive arthritis is almost certainly under-reported. Patients who develop only one or two features of the classic triad — and whose symptoms resolve quickly — may never receive a formal diagnosis. True population incidence is estimated at 30–40 cases per 100,000 persons per year in high-risk populations.

Triggering Infections — Chlamydia, Salmonella, Shigella, Campylobacter, Yersinia

Reactive arthritis requires a triggering infection. The infection typically precedes joint inflammation by 1–4 weeks, during which time the immune system is primed against bacterial antigens. Two main categories of infection trigger the disease:

Genitourinary Triggers

Chlamydia trachomatis is the most common trigger in Western countries, accounting for the majority of sexually acquired reactive arthritis. Chlamydia is an obligate intracellular bacterium that causes urethritis in men and cervicitis in women, though infection is often asymptomatic — particularly in women. Because women with chlamydial infection may have no symptoms, they may present with reactive arthritis without a recognized preceding illness. Chlamydial reactive arthritis follows infection with specific serovars (types) of C. trachomatis, primarily those that infect the urogenital epithelium rather than the eye-infecting strains that cause trachoma.

Importantly, Chlamydia is unique among reactive arthritis triggers in that viable bacterial fragments — though not replicating organisms — have been detected in the synovial fluid and synovial tissue of patients. This has led to debate about whether Chlamydia-triggered reactive arthritis is truly "reactive" or whether it involves a persistent intracellular infection, with implications for antibiotic treatment.

Gastrointestinal Triggers

Several foodborne pathogens trigger reactive arthritis through the gut:

Salmonella (including S. typhimurium and S. enteritidis) — causes reactive arthritis in 2–7% of those infected; typically from contaminated poultry, eggs, or dairy.
Shigella (S. flexneri most commonly) — the first organism clearly associated with reactive arthritis; typically causes dysentery with bloody diarrhea preceding the arthritis by 1–4 weeks.
Campylobacter jejuni — now one of the most common causes of bacterial gastroenteritis in developed countries; reactive arthritis follows in approximately 1–2% of cases.
Yersinia enterocolitica and Y. pseudotuberculosis — particularly important in Scandinavia and northern Europe; can cause prolonged post-infectious arthritis; Yersinia antigens have been detected in synovial tissue.
Clostridium difficile — an emerging trigger; reactive arthritis has been reported following C. difficile colitis, particularly in hospitalized patients.

In all gastrointestinal-triggered cases, the arthritis develops after the diarrheal illness has resolved. Patients (and sometimes clinicians) may not connect the joint symptoms to a gastrointestinal infection that occurred weeks earlier, leading to diagnostic delay.

Pathophysiology and HLA-B27 Association

The fundamental question in reactive arthritis is: why do some people who contract Salmonella or Chlamydia develop arthritis while the vast majority do not? The answer lies principally in a genetic variant — the HLA-B27 allele — and in the host immune response it shapes.

What is HLA-B27?

HLA (Human Leukocyte Antigen) molecules are proteins on the surface of virtually every cell in the body that display protein fragments — peptides — to T cells of the immune system. This display mechanism is how the immune system distinguishes self from non-self. HLA-B27 is a specific variant of the HLA-B molecule. It is present in approximately 6–8% of the general Western population but in 50–80% of patients with reactive arthritis. This striking enrichment indicates that HLA-B27 dramatically increases susceptibility to the disease.

Several overlapping hypotheses explain how HLA-B27 promotes reactive arthritis:

Arthritogenic peptide hypothesis: HLA-B27 may present bacterial peptides to CD8+ T cells in a way that triggers a cross-reactive response against self-tissues in joints. Bacterial antigens "look like" joint proteins to the immune system, causing bystander damage.
Misfolded HLA-B27 hypothesis: HLA-B27 has an unusual tendency to misfold and form aberrant heavy-chain homodimers. Misfolded HLA-B27 in the endoplasmic reticulum triggers an unfolded protein response (UPR) and promotes inflammatory cytokine production, including IL-23 and IL-17, independent of antigen presentation.
Impaired bacterial clearance: HLA-B27 may reduce the efficiency of intracellular killing of bacteria such as Chlamydia and Salmonella, allowing persistent bacterial fragments to sustain the immune response in the joint.

It is critical to understand that HLA-B27 is not diagnostic for reactive arthritis. A positive HLA-B27 test means a person is genetically susceptible; it does not confirm the diagnosis. Many HLA-B27-positive individuals never develop reactive arthritis, and up to 20–50% of reactive arthritis patients are HLA-B27 negative. The test provides supporting evidence but cannot be used alone.

Immune Mechanisms in the Joint

After the triggering infection, bacterial antigens — including lipopolysaccharide (LPS) fragments from gram-negative organisms — are transported from the infection site to synovial tissue, likely via macrophages and dendritic cells that traffic through lymphatics and blood. In the joint, these antigens stimulate T cells and macrophages to produce pro-inflammatory cytokines including TNF-alpha, IL-1, IL-6, and IL-17. The result is a neutrophil-rich synovial fluid (though cultures remain sterile) and pannus formation in chronic cases.

Symptoms — The Classic Triad and Beyond

The textbook presentation of reactive arthritis is the classic Reiter's triad, remembered by the mnemonic: "Can't see, can't pee, can't bend the knee."

Arthritis — joint inflammation (the defining feature)
Urethritis or cervicitis — urogenital inflammation ("can't pee")
Conjunctivitis — eye inflammation ("can't see")

However, only about 30–40% of patients present with the complete triad. Most have partial presentations — arthritis alone or arthritis with one additional feature. Diagnosis does not require all three.

Arthritis Pattern

The arthritis in reactive arthritis is characteristically:

Asymmetric — one knee more affected than the other, for example
Oligoarticular — typically 2–4 joints, not all joints simultaneously
Large joint predominance — knees, ankles, and feet are most commonly affected; wrists and elbows less so
Additive or migratory — new joints become involved while old ones persist, or inflammation moves sequentially from joint to joint

Dactylitis ("sausage digit") — diffuse swelling of an entire finger or toe due to simultaneous flexor tendon sheath inflammation and joint synovitis — is a hallmark feature seen in roughly 20–40% of patients and is characteristic of the spondyloarthropathy family.

Enthesitis — inflammation at tendon and ligament insertion points — is another signature feature. The most common site is the Achilles tendon insertion at the heel, causing heel pain that can be severe and debilitating. The plantar fascia insertion at the heel (causing plantar fasciitis), patellar tendon, and iliac crest are also frequently affected.

Sacroiliitis and spinal involvement occur in a subset of patients, particularly those who are HLA-B27 positive. Low back pain with morning stiffness that improves with movement (inflammatory back pain pattern) can develop alongside peripheral joint disease.

Urogenital Features

In men: urethritis (penile discharge, burning urination), prostatitis, and circinate balanitis — painless, shallow erosions on the glans penis with a serpiginous border that resembles the geographic lesions of pustular psoriasis. In women: cervicitis and sterile pyuria (white cells in urine without bacterial infection).

Eye Features

Conjunctivitis is the most common ocular manifestation — typically bilateral, mild, and self-limited. More serious is anterior uveitis (iritis), which causes eye pain, photophobia, and blurred vision and requires urgent ophthalmologic evaluation, as untreated uveitis can cause permanent vision loss. Uveitis occurs in 10–20% of reactive arthritis patients, more commonly in those who are HLA-B27 positive and those with recurrent disease.

Skin and Mucosal Features

Keratoderma blenorrhagicum — hyperkeratotic papules and plaques on the soles of the feet and palms, and occasionally the scrotum and trunk; clinically and histologically indistinguishable from pustular psoriasis; occurs in about 15% of patients
Nail changes — subungual hyperkeratosis and onycholysis (nail separation) resembling psoriatic nail changes
Oral ulcers — painless (unlike aphthous ulcers) shallow erosions on the palate, tongue, and buccal mucosa; often go unnoticed

Systemic Features

Fever, fatigue, and weight loss can accompany the acute phase. Aortic regurgitation is a rare but serious cardiac complication, seen mainly in chronic or recurrent HLA-B27-positive disease of long duration. Conduction abnormalities have also been reported.

Diagnosis — Clinical Criteria and Tests

There is no single diagnostic test for reactive arthritis. Diagnosis is clinical — based on the pattern of arthritis, evidence of a triggering infection, and exclusion of other conditions. Several classification criteria have been proposed for research purposes, but clinical diagnosis is more flexible.

Clinical Assessment

Key questions in the history:

Did the patient have diarrhea, urethritis, or cervicitis in the 1–6 weeks before joint symptoms began?
Is there heel pain (enthesitis), sausage digits (dactylitis), or back pain suggesting spondyloarthropathy features?
Are there skin, eye, or mucosal features consistent with the disease?

Laboratory Testing

Inflammatory markers: ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) are elevated in active disease but are nonspecific.
Complete blood count: Leukocytosis (elevated white cells) and anemia of inflammation may be present.
Rheumatoid factor and anti-CCP antibodies: Should be negative. Positivity should prompt reconsideration of rheumatoid arthritis.
ANA (antinuclear antibody): Typically negative; positivity raises concern for lupus or another connective tissue disease.
HLA-B27 testing: Present in 50–80% of patients; supports the diagnosis but is neither necessary nor sufficient. Useful when the clinical picture is uncertain.
Infection testing: Urine NAAT (nucleic acid amplification test) for Chlamydia trachomatis; stool culture for Salmonella, Shigella, Campylobacter, Yersinia; Yersinia serology in appropriate epidemiological settings. Note that by the time arthritis develops, stool cultures for gastrointestinal pathogens are often negative, as the infection has cleared.
Urinalysis: May show sterile pyuria in urogenital-triggered cases.

Synovial Fluid Analysis

Joint aspiration (arthrocentesis) is important primarily to exclude septic arthritis, which is a medical emergency requiring urgent antibiotic treatment and drainage. In reactive arthritis, the synovial fluid is inflammatory — typically 5,000–50,000 white cells per microliter, predominantly neutrophils — but cultures are sterile. Gout and pseudogout can be excluded by examining the fluid for crystals under polarized light microscopy.

Imaging

X-rays of affected joints are often normal in early disease. In chronic cases, periostitis (new bone formation along the shaft of small bones of the feet) and enthesophytes (bony spurs at tendon insertions) can be seen. MRI is more sensitive for detecting early sacroiliitis and enthesitis. Ultrasound is useful for guiding joint aspiration and detecting enthesitis and tendon sheath inflammation at the bedside.

Treatment — NSAIDs, Antibiotics, DMARDs

Treatment of reactive arthritis is tailored to disease severity, the presence of an active triggering infection, and whether the disease is acute, recurrent, or chronic.

NSAIDs — First-Line Therapy

Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of treatment for most patients with reactive arthritis. Indomethacin (25–50 mg three times daily), naproxen, diclofenac, and other NSAIDs provide significant relief of joint pain and stiffness. They reduce inflammation but do not alter the underlying immune process or accelerate resolution of the disease. NSAIDs are used at regular dosing schedules rather than as needed for maximum benefit. Gastrointestinal protection with a proton pump inhibitor is recommended for longer-term use. Patients with cardiovascular risk factors should discuss NSAID use with their physician given the increased cardiovascular risk associated with these medications.

Corticosteroids

Intra-articular corticosteroid injections — injecting methylprednisolone or triamcinolone directly into an inflamed joint — provide rapid, targeted relief and can dramatically reduce pain and swelling in a specific joint within days. They are particularly useful for one or two severely inflamed joints. Systemic oral corticosteroids (prednisone) are sometimes used for severe multi-joint disease or significant extra-articular features, but prolonged use carries well-known risks (weight gain, bone loss, blood sugar elevation, immune suppression) and should be minimized.

Antibiotics

The role of antibiotics in reactive arthritis is nuanced and remains an area of active debate:

Active Chlamydia infection: If a current Chlamydia trachomatis infection is confirmed (e.g., positive NAAT), it should be treated with standard antibiotic regimens — typically a single dose of azithromycin 1 g or a 7-day course of doxycycline 100 mg twice daily. Treating the active infection is the standard of care and important to prevent transmission and complications. However, randomized controlled trials have consistently failed to demonstrate that treating active chlamydial infection shortens the course of the arthritis.
Prolonged antibiotics for Chlamydia-triggered reactive arthritis: Several trials have investigated whether a prolonged course of antibiotics (3–6 months of doxycycline or a combination of rifampicin and azithromycin) can treat the persistent chlamydial fragments hypothesized to perpetuate the arthritis. Results are mixed; the largest trials have not shown clear benefit for chronic reactive arthritis, but some researchers continue to pursue this hypothesis in carefully selected patients.
Gastrointestinal-triggered cases: There is no evidence that antibiotics for gastrointestinal-triggered reactive arthritis affect the arthritis course. By the time arthritis develops, the stool infection has typically resolved, and antibiotic treatment is not indicated for the arthritis itself.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

For patients whose arthritis persists beyond 3–6 months, DMARDs are introduced:

Sulfasalazine (500 mg–1 g twice daily, increasing gradually) — the most commonly used DMARD for reactive arthritis; supported by small randomized trials showing modest benefit in chronic disease; requires monitoring of liver function and blood counts.
Methotrexate (15–25 mg weekly) — used for severe or refractory peripheral joint disease; similar to its use in rheumatoid arthritis; requires folate supplementation and regular monitoring.
Azathioprine — an alternative immunosuppressive for methotrexate-intolerant patients.

Biologic Therapies

For patients with severe, chronic reactive arthritis refractory to DMARDs — especially those with significant axial (spinal) disease or recurrent uveitis — TNF-alpha inhibitors (etanercept, adalimumab, infliximab) have been used successfully, drawing on evidence from their established efficacy in ankylosing spondylitis (a closely related spondyloarthropathy). Use of biologics for reactive arthritis is off-label and requires specialist supervision, but they can provide dramatic benefit in carefully selected patients. Screening for latent tuberculosis and hepatitis B is mandatory before starting biologics.

Physical Therapy

Physical therapy and targeted exercises are important throughout the disease course to maintain joint range of motion, strengthen supporting muscles, and prevent deconditioning. A physical therapist experienced in inflammatory arthritis can design a program appropriate for each patient's specific joint involvement.

Natural and Nutritional Approaches

Natural and nutritional approaches are not substitutes for medical treatment but can meaningfully reduce inflammation, support immune function, and improve quality of life alongside standard therapy. Always discuss supplements with your treating physician, as some may interact with medications.

Omega-3 Fatty Acids

Omega-3 fatty acids — found in fatty fish (salmon, sardines, mackerel), fish oil supplements, and flaxseed — have well-documented anti-inflammatory effects. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) compete with arachidonic acid in inflammatory pathways, reducing production of pro-inflammatory prostaglandins and leukotrienes. In randomized trials in rheumatoid arthritis — a closely related inflammatory arthritis — fish oil supplementation significantly reduced joint swelling, morning stiffness, and need for NSAIDs. Typical therapeutic doses in studies are 2–4 grams of combined EPA+DHA per day. Fish oil has a favorable safety profile and is widely recommended as an adjunct in inflammatory arthritis.

Probiotics for Gut-Triggered Cases

For patients whose reactive arthritis was triggered by a gastrointestinal pathogen, restoring gut microbiome health may be particularly relevant. The gut-immune axis is central to spondyloarthropathy pathogenesis — subclinical gut inflammation is detectable in a large proportion of reactive arthritis patients, and dysbiosis (microbial imbalance) may perpetuate systemic immune activation. Probiotic strains including Lactobacillus rhamnosus, L. acidophilus, and Bifidobacterium species have shown anti-inflammatory properties in gastrointestinal disease models. Fermented foods (yogurt, kefir, sauerkraut, kimchi) provide live bacteria and prebiotic fiber that support microbiome diversity. Evidence specific to reactive arthritis is limited but mechanistically plausible.

Vitamin D

Vitamin D deficiency is highly prevalent in patients with inflammatory arthritis and correlates with disease severity. Vitamin D receptors are present on immune cells, and the active form of vitamin D (1,25-dihydroxyvitamin D3) modulates both innate and adaptive immunity, promoting regulatory T cell differentiation and dampening pro-inflammatory Th17 responses (the IL-17 pathway that is particularly relevant in spondyloarthropathies). Maintaining serum 25-OH vitamin D levels above 40–60 ng/mL through sensible sun exposure and supplementation (1,000–4,000 IU/day of vitamin D3) is a low-risk intervention that supports immune regulation and bone health — the latter particularly important given the risk of bone loss with corticosteroid use.

Zinc

Zinc is essential for immune function and wound healing and plays a role in regulating inflammatory cytokine production. Zinc deficiency impairs T cell function and has been associated with increased susceptibility to infections — including the bacterial infections that trigger reactive arthritis. Adequate dietary zinc from sources such as oysters, beef, pumpkin seeds, and legumes, or moderate supplementation (8–15 mg/day), supports immune competence. Very high-dose zinc supplementation (above 40 mg/day) can impair copper absorption and should be avoided.

Anti-Inflammatory Diet

A Mediterranean-style diet rich in vegetables, fruits, whole grains, olive oil, legumes, and fatty fish while low in refined sugars, processed foods, and red meat has demonstrated anti-inflammatory effects in multiple studies of inflammatory arthritis and general inflammation markers. Minimizing dietary triggers of inflammation — particularly excess refined carbohydrates and ultra-processed foods high in omega-6 fatty acids — creates a physiological environment less hospitable to chronic inflammation.

Turmeric and Curcumin

Curcumin, the active compound in turmeric (Curcuma longa), inhibits NF-kB, a master regulator of inflammatory gene expression, and has demonstrated anti-inflammatory properties in laboratory and clinical studies of inflammatory joint disease. Bioavailability is low with standard turmeric powder but is improved significantly with piperine (black pepper extract) co-administration or phospholipid complex formulations. As an adjunct to NSAIDs, curcumin may allow lower NSAID doses in some patients.

Disease Course and Prognosis

For most patients, reactive arthritis is a self-limited condition. The majority of patients — approximately 60–80% — experience resolution of their arthritis within 6–12 months of onset. Many require no treatment beyond a short course of NSAIDs. Skin, eye, and urogenital features typically resolve within weeks to months.

However, the prognosis is not uniformly favorable:

Approximately 15–20% of patients develop chronic reactive arthritis — persistent inflammatory joint disease lasting more than one year. These patients often require long-term DMARD or biologic therapy.
Another 15–30% experience recurrent episodes — discrete flares of arthritis, often triggered by subsequent infections, with periods of remission in between.
HLA-B27-positive patients have a higher risk of chronic disease, recurrent uveitis, and progression to ankylosing spondylitis — a more severe axial spondyloarthropathy with sacroiliitis and spinal fusion.
The triggering organism also influences prognosis. Chlamydia-triggered reactive arthritis tends to be more chronic and recurrent than gastrointestinal-triggered disease. Yersinia-triggered cases also carry a significant risk of chronicity.

Factors associated with a worse prognosis include: HLA-B27 positivity, hip joint involvement, erythrocyte sedimentation rate persistently elevated above 30 mm/h, poor response to NSAIDs in the first 2 months, and onset before age 16. Early specialist referral and aggressive treatment in patients with these risk factors may reduce the risk of long-term joint damage.

Complications

While most patients recover fully, complications can arise, particularly in chronic or recurrent disease:

Chronic joint damage: Persistent synovitis can lead to cartilage erosion, bone damage, and permanent joint deformity — similar to but generally less severe than rheumatoid arthritis.
Ankylosing spondylitis: In HLA-B27-positive patients with repeated episodes, sacroiliitis can progress to full ankylosis (fusion) of the sacroiliac joints and the spine — a severe, disabling form of axial spondyloarthropathy.
Recurrent or chronic uveitis: Episodes of anterior uveitis can recur over years; if untreated or inadequately managed, uveitis can lead to permanent visual impairment from glaucoma, cataracts, or macular edema.
Aortic valve insufficiency: In a small percentage of patients with chronic HLA-B27-associated spondyloarthropathy, inflammation around the aortic root leads to aortic regurgitation, sometimes requiring valve replacement.
Enthesopathy and tendon damage: Chronic enthesitis — particularly at the Achilles tendon — can lead to tendon calcification, chronic pain, and reduced mobility even after the acute arthritis resolves.
Psychological impact: Chronic or recurrent inflammatory arthritis significantly impacts quality of life, work capacity, and mental health. Depression and anxiety are more prevalent in reactive arthritis patients with chronic disease.

Prevention — Infection Control

Because reactive arthritis requires a triggering infection, preventing the infection prevents the arthritis. Practical prevention strategies include:

Preventing Sexually Transmitted Infections

Condom use consistently and correctly reduces the risk of Chlamydia trachomatis transmission.
Regular chlamydia screening in sexually active individuals under 25 — and in older individuals with new or multiple partners — allows early detection and treatment before arthritis develops. The CDC recommends annual chlamydia and gonorrhea screening for all sexually active women under 25.
Partner notification and treatment: Treating sexual partners of confirmed chlamydial infections prevents reinfection and ongoing transmission in the community.

Preventing Foodborne Infections

Safe food handling: Thoroughly cook poultry, eggs, and meat; avoid cross-contamination between raw and cooked foods; refrigerate perishables promptly.
Hand washing with soap and water after handling raw meat, before cooking, and before eating remains the single most effective way to prevent foodborne bacterial infection.
Avoid unpasteurized dairy and raw egg products, which are common sources of Salmonella.
Safe water: When traveling in regions with unreliable water sanitation, drink bottled or boiled water; avoid ice and raw produce washed in tap water.

For Individuals with Prior Reactive Arthritis

Patients who have had one episode of reactive arthritis — especially HLA-B27-positive individuals — should be particularly vigilant about infection prevention, as each new triggering infection risks a recurrence or chronic escalation. Some rheumatologists recommend that HLA-B27-positive patients with a history of reactive arthritis use prophylactic doxycycline or azithromycin if they develop recurrent or untreatable chlamydial infections, though this remains controversial and is not standard guideline practice.

Key Research Papers

Back to Table of Contents

Connections